Start here if you're new
what it is
Masco makes faucets, paint, and other home-improvement products for your house.
how it gets paid
Last year Masco made $7.6B in revenue. Delta Faucet and shower fixtures was the main engine at $2.5B, or 33% of sales.
why growth slowed
Revenue fell 3.4% last year. The 1.23% EPS surprise matters because investors buy steady execution.
what just happened
Masco beat by 1.23%, but annual revenue still fell 3.4% to $7.6B.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
90/100 earnings predictability — you can trust these numbers
17.6x trailing p/e — the market's not buying it — or you found a deal
1.9% dividend yield — cash in your pocket every quarter
34.0% return on capital — every dollar works hard here
xvary composite: 70/100 — average
What they do
Masco makes faucets, paint, and other home-improvement products for your house.
Your bathroom brand choice is sticky. Delta, Behr, and Hansgrohe help Masco earn a 34.0% return on capital, which is profit on money invested. Leaving means changing the faucet, repainting the room, and paying for the hassle.
How they make money
$7.6B
annual revenue · their business grew -3.4% last year
Delta Faucet and shower fixtures
$2.5B
+3.0%
Behr paint and coatings
$1.9B
+2.0%
Hansgrohe bath fittings
$1.4B
+4.0%
Decorative hardware and accessories
$1.2B
1.0%
Other plumbing and home-improvement brands
$0.6B
+0.5%
The products that matter
manufactures plumbing fixtures
Plumbing Products
part of a $7.6B company
this is the most obvious housing read-through in the story. the current snapshot does not break out segment revenue, so you cannot see the mix — only that the full company produced $7.6B last year.
core demand
sells decorative products
Decorative Architectural Products
inside the same $7.6B base
this is the other side of the portfolio. again, the current data does not show the revenue split, which means you are underwriting the whole $7.6B business without a clean segment-level margin read.
mix matters
Key numbers
$7.6B
annual sales
That is the size of the machine. You get a $7.6B business that still earns 34.0% on capital.
34.0%
return on capital
return on capital → profit on money invested → 34.0%, which says Masco squeezes a lot out of each dollar.
18.5%
operating margin
operating margin → profit after running the business → 18.5%, which leaves room for shocks but not much slop.
1.9%
dividend yield
You get paid 1.9% a year to wait, which is less exciting than the business quality.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 75 / 100
- long-term debt $3.0B (17% of capital)
- net profit margin 10.9% — keeps 11 cents of every dollar in revenue
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in MAS 3 years ago → it's now worth $14,150.
The index would have given you $14,540.
source: institutional data · total return
What just happened
beat estimates
Masco beat by 1.23%, but annual revenue still fell 3.4% to $7.6B.
EPS came in at $0.82 vs $0.81 expected. Gross margin was 35.9%, so the quarter was more about execution than demand.
$5.8B
revenue
$3.06
eps
35.9%
gross margin
EPS beat
The 1.23% EPS surprise matters because investors buy steady execution, and the 3.4% revenue decline says demand is still weak.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is a housing-led slowdown in repair, remodel, and new construction demand.
med
housing turnover slowdown
Masco sells the kinds of products people buy when homes change hands or get renovated. fewer transactions usually mean fewer projects.
This pressure runs through the full $7.6B revenue base, not one side business.
med
repair-and-remodel pullback
The business is tied to home improvement spending. if consumers delay kitchen, bath, and decorative projects, volume slows fast.
The latest quarter already showed revenue down 1.9% from a year ago. if that trend sticks, the growth narrative changes.
med
input cost inflation
Raw materials, freight, and manufacturing costs can move faster than pricing. that matters more in a mature product category than in software land.
With a 10.9% net margin, there is cushion here, but not endless cushion.
med
earnings quality gets tested if sales stay soft
EPS rose 17% last quarter even as revenue fell 1.9% from a year ago. that is a nice outcome for one quarter. it gets harder to repeat if demand stays weak.
If sales softness persists, the $4.20 fy2026 and $4.60 fy2027 EPS expectations become harder to defend.
a housing slowdown does not hit one small segment here. it hits the whole $7.6B company, and the current 10.9% net margin is good enough to matter but not so high that you can ignore volume risk.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
next earnings on april 30, 2026
watch whether revenue improves from the latest $1.79B and whether EPS resilience holds.
trend
the growth comedown
full-year revenue grew 31.1%, but the latest quarter fell 1.9% from a year ago. that gap needs an explanation.
risk
margin pressure
10.9% net margin is healthy, but not immune. rising input costs would show up here first.
metric
EPS estimates
The current markers are $4.20 for fy2026 and $4.60 for fy2027. if those slip, the mid-teens multiple will look less cheap.
Analyst rankings
short-term outlook
top 20%
momentum score 2 — analysts expect above-average price performance in the year ahead. in human-speak, they like the setup more than the average stock.
risk profile
average
stability score 3 — a typical risk profile. not especially defensive, not unusually fragile.
chart momentum
average
technical score 3 — the stock is moving roughly with the market, not sending a dramatic signal either way.
earnings predictability
90 / 100
management tends to produce reliable numbers. you usually do not get wild surprises here.
source: institutional data
Institutional activity
institutions have been net selling for 2 consecutive quarters — 254 buyers vs. 378 sellers in 4q2025. total institutional holdings: 0.2B shares. net selling for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$55
$102
$70
current price
$79
target midpoint · +13% from current · 3-5yr high: $135 (+95% · 19% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive